U.S. Markets close in 1 hr 56 mins

Eli Lilly and Company (LLY)


NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
81.95-2.79 (-3.29%)
As of 2:04PM EDT. Market open.
People also watch
BMYMRKABTGSKJNJ
Full screen
Previous Close84.74
Open83.74
Bid81.86 x 300
Ask81.87 x 500
Day's Range80.77 - 84.40
52 Week Range64.18 - 86.72
Volume8,855,021
Avg. Volume3,546,585
Market Cap86.21B
Beta0.17
PE Ratio (TTM)39.63
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (2.46%)
Ex-Dividend Date2017-08-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Eli Lilly Tumbles On Arthritis Drug Delay, Light Q2 Sales
    Investor's Business Daily38 minutes ago

    Eli Lilly Tumbles On Arthritis Drug Delay, Light Q2 Sales

    A delay in getting its rheumatoid arthritis drug to market by at least 18 months sent Eli Lilly shares lower Tuesday.

  • Zacks46 minutes ago

    3 Buy-Ranked Stocks That Just Crushed Earnings

    These earnings reports not only demonstrate the past quarter???s solid performance, but they also preview its financial outlook over its next operational quarter.

  • Barrons.com2 hours ago

    Eli Lilly: What the Heck Just Happened?

    Eli Lilly (LLY) beat earnings forecasts today, but all anyone wants to talk about is a delayed filing for its the rheumatoid arthritis drug it's developing with Incyte (INCY). Eli Lilly reported an adjusted profit of $1.11, topping the Street consensus for $1.05, on sales of $5.82 billion, above expectations for $5.59 billion. Unfortunately, Eli Lilly and Incyte announced that their resubmission of a New Drug Application for their rheumatoid arthritis drug, baricitinib, would be delayed.